Oculis (OCS) Competitors $16.76 -0.57 (-3.26%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. BHC, KYMR, SRRK, AMRX, XENE, CRNX, HCM, RARE, MOR, and ARWRShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Crinetics Pharmaceuticals (CRNX), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Bausch Health Cos Kymera Therapeutics Scholar Rock Amneal Pharmaceuticals Xenon Pharmaceuticals Crinetics Pharmaceuticals HUTCHMED Ultragenyx Pharmaceutical MorphoSys Arrowhead Pharmaceuticals Oculis (NASDAQ:OCS) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings. Do institutionals and insiders hold more shares of OCS or BHC? 22.3% of Oculis shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 8.1% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts recommend OCS or BHC? Oculis currently has a consensus price target of $35.75, indicating a potential upside of 113.10%. Bausch Health Cos has a consensus price target of $9.00, indicating a potential upside of 25.79%. Given Oculis' stronger consensus rating and higher probable upside, equities analysts plainly believe Oculis is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor OCS or BHC? In the previous week, Oculis had 9 more articles in the media than Bausch Health Cos. MarketBeat recorded 24 mentions for Oculis and 15 mentions for Bausch Health Cos. Oculis' average media sentiment score of 0.33 beat Bausch Health Cos' score of 0.09 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 6 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Bausch Health Cos 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, OCS or BHC? Bausch Health Cos has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K939.03-$97.43M-$2.67-6.28Bausch Health Cos$9.63B0.28-$46M$0.2627.52 Which has more risk & volatility, OCS or BHC? Oculis has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Is OCS or BHC more profitable? Bausch Health Cos has a net margin of 0.99% compared to Oculis' net margin of -13,958.12%. Oculis' return on equity of -90.31% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,958.12% -90.31% -67.85% Bausch Health Cos 0.99%-852.36%5.25% SummaryBausch Health Cos beats Oculis on 9 of the 16 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$733.27M$3.06B$5.75B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-6.2921.2030.7626.60Price / Sales939.03383.15459.33120.41Price / CashN/A44.4437.7659.36Price / Book4.238.1010.036.70Net Income-$97.43M-$54.08M$3.27B$265.68M7 Day Performance-5.75%2.77%3.36%3.42%1 Month Performance-6.28%3.89%4.58%1.09%1 Year Performance38.76%18.96%44.38%23.94% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.9609 of 5 stars$16.77-3.3%$35.75+113.2%+45.5%$731.35M$780K-6.272News CoverageEarnings ReportAnalyst ForecastBHCBausch Health Cos4.694 of 5 stars$8.02-3.8%$9.00+12.2%+22.1%$3.09B$9.63B30.8520,700Analyst RevisionKYMRKymera Therapeutics3.0842 of 5 stars$43.62+2.3%$59.11+35.5%-13.6%$3.05B$47.07M-12.57170News CoverageSRRKScholar Rock4.5633 of 5 stars$31.52+0.4%$45.14+43.2%+280.5%$3.02B$33.19M-10.83140AMRXAmneal Pharmaceuticals3.268 of 5 stars$9.26-2.0%$11.60+25.3%+10.4%$2.97B$2.85B926.938,100Positive NewsInsider TradeXENEXenon Pharmaceuticals2.2809 of 5 stars$37.82-1.1%$53.20+40.7%-5.0%$2.95B$7.50M-10.65210CRNXCrinetics Pharmaceuticals3.6453 of 5 stars$29.74-3.2%$68.86+131.5%-44.2%$2.89B$1.04M-7.24210News CoveragePositive NewsInsider TradeHCMHUTCHMED2.6637 of 5 stars$16.43-0.1%$28.00+70.4%-13.6%$2.87B$602.20M0.001,811RAREUltragenyx Pharmaceutical4.6665 of 5 stars$29.70+0.0%$81.50+174.4%-47.8%$2.86B$610.16M-5.371,294MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsARWRArrowhead Pharmaceuticals3.7376 of 5 stars$19.91-2.9%$43.14+116.7%-9.0%$2.84B$3.55M-15.55400Positive News Related Companies and Tools Related Companies BHC Competitors KYMR Competitors SRRK Competitors AMRX Competitors XENE Competitors CRNX Competitors HCM Competitors RARE Competitors MOR Competitors ARWR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access